Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma

Highly Entrenched Rituxan Could Prove Tough To Dislodge

Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.

Cancer-cells-pink-color_1200x675
Roche presented data at ASCO on its two CD20xCD3-targeting bispecific antibodies • Source: Shutterstock

With high response rates in heavily pretreated non-Hodgkin’s lymphoma (NHL) patients, Roche Holding AG hopes to eventually move its CD20-targeting bispecific antibodies mosunetuzumab and glofitamab into earlier lines of therapy, where they could potentially replace long-established anti-CD20 monoclonal antibody players like its own Rituxan (rituximab) and Gazyva (obinutuzumab). But it’s more likely that the bispecifics will fit into certain niches of diffuse large B-cell lymphoma (DLBCL) patients who do not respond well to Rituxan/chemotherapy approaches.

Rituxan has long been a dominant force in NHL and similar cancers and will be a hard drug to unseat,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Conferences

Merus Raises $300m After ASCO Success

 

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.